Therapies for Allergic Inflammation: Refining Strategies to Induce Tolerance

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2012 May 8

PMID 22561837

Citations 103

Authors

Cezmi A Akdis

Affiliations

Soon will be listed here.

Abstract

Current therapies for asthma and allergy are relatively safe and effective at controlling symptoms but do not change the chronic course of disease. There is no established method to prevent asthma and allergy, and major unmet needs in this area include the better control of the severe forms of these diseases and the developments of curative therapies. Two major therapeutic strategies for asthma and allergy are currently being developed, and I here discuss the advances and challenges for future therapeutic development in these two areas. The first approach, allergen-specific immunotherapy, aims to induce specific immune tolerance and has a long-term disease-modifying effect. The second approach is the use of biological immune response modifiers to decrease pathological immune responses. Combination strategies using both of these approaches may also provide a route for addressing the unmet clinical needs in allergic diseases.

Citing Articles

Allergy Inhibition Using Naturally Occurring Compounds Targeting Thymic Stromal Lymphopoietin Pathways: a Comprehensive Review.

Vinh L, Lee K, Han Y, Kim Y, Kim S, Shah A Biomol Ther (Seoul). 2025; 33(2):249-267.

PMID: 39933953 PMC: 11893497. DOI: 10.4062/biomolther.2024.177.

Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases.

Zhao G, Wang Z, Zhang J, Lin Y, Zhou T, Liu K J Inflamm Res. 2024; 17:6375-6388.

PMID: 39296644 PMC: 11410029. DOI: 10.2147/JIR.S471963.

Activation of the aryl hydrocarbon receptor improves allergen-specific immunotherapy of murine allergic airway inflammation: a novel adjuvant option?.

Heine S, Alessandrini F, Grosch J, Grass C, Heldner A, Schnautz B Front Immunol. 2024; 15:1397072.

PMID: 38915403 PMC: 11194380. DOI: 10.3389/fimmu.2024.1397072.

Hispidulin Alleviates Mast Cell-Mediated Allergic Airway Inflammation through FcεR1 and Nrf2/HO-1 Signaling Pathway.

Jeong S, Kim Y, Lee D, Kim S, Lee S Antioxidants (Basel). 2024; 13(5).

PMID: 38790633 PMC: 11118000. DOI: 10.3390/antiox13050528.

The barrier-protective effect of β-eudesmol against type 2-inflammatory cytokine-induced tight junction disassembly in airway epithelial cells.

Tharabenjasin P, Moonwiriyakit A, Sontikun J, Timpratueang K, Kuno S, Aiebchun T PLoS One. 2024; 19(4):e0302851.

PMID: 38687777 PMC: 11060601. DOI: 10.1371/journal.pone.0302851.

References

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M, Valent P . Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14677-82. PMC: 521981. DOI: 10.1073/pnas.0404735101. View

Hitomi K, Tahara-Hanaoka S, Someya S, Fujiki A, Tada H, Sugiyama T . An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. Nat Immunol. 2010; 11(7):601-7. DOI: 10.1038/ni.1886. View

Casale T, Condemi J, Laforce C, Nayak A, Rowe M, Watrous M . Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001; 286(23):2956-67. DOI: 10.1001/jama.286.23.2956. View

Borish L, Nelson H, Lanz M, Claussen L, Whitmore J, Agosti J . Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999; 160(6):1816-23. DOI: 10.1164/ajrccm.160.6.9808146. View

Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R . Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol. 2008; 121(6):1515-6. DOI: 10.1016/j.jaci.2008.03.007. View

Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L . Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009; 123(1):167-173.e7. DOI: 10.1016/j.jaci.2008.10.044. View

Dillon S, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell S . Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752-60. DOI: 10.1038/ni1084. View

Veldhoen M, Uyttenhove C, Van Snick J, Helmby H, Westendorf A, Buer J . Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008; 9(12):1341-6. DOI: 10.1038/ni.1659. View

Andrews A, Holloway J, Holgate S, Davies D . IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol. 2006; 176(12):7456-61. DOI: 10.4049/jimmunol.176.12.7456. View

10.

Sato T, Komai M, Iwase M, Kobayashi K, Tahara H, Ohshima E . Inhibitory effect of the new orally active CCR4 antagonist K327 on CCR4+CD4+ T cell migration into the lung of mice with ovalbumin-induced lung allergic inflammation. Pharmacology. 2009; 84(3):171-82. DOI: 10.1159/000235748. View

11.

Wu A, Paltiel A, M Kuntz K, Weiss S, Fuhlbrigge A . Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007; 120(5):1146-52. PMC: 3476046. DOI: 10.1016/j.jaci.2007.07.055. View

12.

Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M . Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol. 2007; 179(8):5309-16. DOI: 10.4049/jimmunol.179.8.5309. View

13.

Rothenberg M, Klion A, Roufosse F, Kahn J, Weller P, Simon H . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358(12):1215-28. DOI: 10.1056/NEJMoa070812. View

14.

Berry M, Hargadon B, Shelley M, Parker D, Shaw D, Green R . Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354(7):697-708. DOI: 10.1056/NEJMoa050580. View

15.

Sands M, Blume J, Schwartz S . Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007; 120(4):979-81. DOI: 10.1016/j.jaci.2007.07.041. View

16.

Romano A, Torres M, Castells M, Sanz M, Blanca M . Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011; 127(3 Suppl):S67-73. DOI: 10.1016/j.jaci.2010.11.047. View

17.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

18.

Akdis C, Blaser K . Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol. 2001; 22(4):175-8. DOI: 10.1016/s1471-4906(01)01862-2. View

19.

Wenzel S, Wilbraham D, Fuller R, Burmeister Getz E, Longphre M . Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; 370(9596):1422-31. DOI: 10.1016/S0140-6736(07)61600-6. View

20.

Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R . Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004; 199(11):1567-75. PMC: 2211782. DOI: 10.1084/jem.20032058. View